What are the epidemiology and pathophysiology of Chediak-Higashi syndrome?

Chediak-Higashi Syndrome: Epidemiology and Pathophysiology

Epidemiology

Chediak-Higashi syndrome (CHS) is an extremely rare autosomal recessive disorder with an estimated incidence of approximately 1:100,000 to 1:1,000 live births globally. 1, 2 Based on data from Japan's nationwide survey, approximately 1-2 new cases are diagnosed annually in that country 1. The disease shows no clear ethnic or geographic predilection, though specific populations may have founder mutations.

Key Epidemiologic Features:

• Inheritance pattern: Autosomal recessive
• Incidence: Extremely rare (1:100,000-1,000)
• Age of presentation: Most commonly in early childhood (classic form), though atypical forms can present later
• Mortality: Historically very high in untreated patients, with most dying in childhood from infection or hemophagocytic lymphohistiocytosis (HLH) 3

Pathophysiology

CHS results from biallelic mutations in the lysosomal trafficking regulator (LYST) gene, which encodes a massive 430 kDa cytosolic protein involved in vesicle trafficking and lysosomal biogenesis. 3, 4

Molecular Mechanism:

The LYST protein functions as a vesicle trafficking regulatory protein, likely involved in:

• Lysosome fusion events
• Sorting of lysosomal proteins to endosomes
• Regulation of lysosomal size and function 3, 5

The protein contains three critical conserved domains 6:

• HEAT repeat motif at the amino-terminus (multiple α-helices)
• BEACH domain containing the WIDL sequence
• WD40 repeat motif (protein-protein interaction domain)

Cellular Consequences:

When LYST is dysfunctional, proteins accumulate abnormally in lysosomes, causing characteristic enlargement of lysosomes and related organelles 3:

1. Melanosomes → partial oculocutaneous albinism
2. Platelet dense bodies → bleeding diathesis
3. Cytolytic granules in NK cells and CTLs → immunodeficiency
4. Neuronal lysosomes → progressive neurodegeneration

Genotype-Phenotype Correlation:

The severity of CHS directly correlates with mutation type 2, 5:

• Classic (severe) form: Nonsense or frameshift mutations → complete loss of function

  • Early childhood presentation
  • Severe immunodeficiency with recurrent pyogenic infections
  • High risk of life-threatening HLH (accelerated phase)
  • Poor prognosis without hematopoietic stem cell transplantation (HSCT)

• Atypical (mild) form: Missense mutations → partial protein function

  • Later presentation
  • Milder immunologic symptoms
  • Inevitable progressive neurological impairment
  • Longer survival but eventual neurodegeneration

Pathognomonic Feature:

Giant azurophilic lysosomal granules in all granulated cells (hematopoietic cells and melanocytes) are pathognomonic for CHS 3. This distinguishes CHS from related disorders like Griscelli syndrome and Hermansky-Pudlak syndrome 4.

Clinical Manifestations Result From:

1. Immune dysfunction: Impaired NK cell and cytotoxic T lymphocyte degranulation → recurrent pyogenic bacterial infections (skin, respiratory tract) 3, 1

2. Hemophagocytic lymphohistiocytosis: CHS is a member of familial HLH disorders; virtually all untreated patients eventually develop this "accelerated phase" characterized by:

   • High unremitting fever
   • Hepatosplenomegaly
   • Pancytopenia
   • Neurological deterioration (confusion, seizures, coma)
   • Without aggressive treatment, usually fatal 3

3. Neurological dysfunction: Progressive cerebellar, spinal, and peripheral neuropathies; cognitive impairment 3, 2

4. Bleeding tendency: Platelet dysfunction from abnormal dense bodies 3

5. Oculocutaneous albinism: Defective melanosome trafficking → photophobia, nystagmus 3

Critical Clinical Pitfall:

HSCT successfully treats the immunologic and hematologic manifestations but does NOT prevent or correct the progressive neurological deterioration 3, 2. Even patients who undergo successful HSCT will eventually develop neurological difficulties, making this a critical counseling point for families.